转移性-话题@MedSci

#转移性#

975篇内容 | 3396人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386974, encodeId=e7db13869e4e3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估, objectType=article, longId=723989, objectId=0551e2398931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0551e2398931, replyNumber=0, likeNumber=77, createdTime=2022-04-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0551e2398931, moduleTitle=AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0551e2398931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386972, encodeId=f1fa13869e2c8, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=120, createdTime=2022-04-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386973, encodeId=593713869e365, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, objectType=article, longId=723824, objectId=cc6fe23824f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc6fe23824f3, replyNumber=0, likeNumber=87, createdTime=2022-04-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc6fe23824f3, moduleTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc6fe23824f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386970, encodeId=a8c913869e0f4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11, objectType=article, longId=723574, objectId=fef6e2357411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6e2357411, replyNumber=0, likeNumber=74, createdTime=2022-04-07, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6e2357411, moduleTitle=Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6e2357411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386969, encodeId=1b1e138696989, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后, objectType=article, longId=723550, objectId=0c6ae23550d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6ae23550d2, replyNumber=0, likeNumber=71, createdTime=2022-04-07, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6ae23550d2, moduleTitle=Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6ae23550d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386971, encodeId=3ffd13869e112, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌, objectType=article, longId=723523, objectId=d89be23523ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89be23523ff, replyNumber=0, likeNumber=98, createdTime=2022-04-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89be23523ff, moduleTitle=Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89be23523ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386968, encodeId=affb13869687f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=723399, objectId=0052e23399a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0052e23399a4, replyNumber=0, likeNumber=90, createdTime=2022-04-05, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0052e23399a4, moduleTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0052e23399a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386967, encodeId=84ff138696e46, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌, objectType=article, longId=302189, objectId=e07a302189c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e07a302189c4, replyNumber=0, likeNumber=63, createdTime=2022-04-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e07a302189c4, moduleTitle=J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e07a302189c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386966, encodeId=1f80138696667, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, objectType=article, longId=301648, objectId=93a0301648a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a0301648a6, replyNumber=0, likeNumber=59, createdTime=2022-03-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a0301648a6, moduleTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a0301648a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386965, encodeId=c5a3138696515, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：达洛鲁胺对转移性激素敏感性前列腺癌生存率的影响, objectType=article, longId=301583, objectId=f6873015839b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6873015839b, replyNumber=0, likeNumber=69, createdTime=2022-03-26, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6873015839b, moduleTitle=NEJM：达洛鲁胺对转移性激素敏感性前列腺癌生存率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6873015839b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386964, encodeId=99a813869644c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, objectType=article, longId=301463, objectId=dae03014634c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae03014634c, replyNumber=0, likeNumber=89, createdTime=2022-03-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae03014634c, moduleTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae03014634c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386963, encodeId=9c9e138696304, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, objectType=article, longId=301244, objectId=cf6f3012449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6f3012449f, replyNumber=0, likeNumber=68, createdTime=2022-03-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6f3012449f, moduleTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf6f3012449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386962, encodeId=6eaa138696245, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=30, createdTime=2022-03-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386961, encodeId=7aa3138696139, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, objectType=article, longId=301132, objectId=c2d23011325d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d23011325d, replyNumber=0, likeNumber=68, createdTime=2022-03-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d23011325d, moduleTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d23011325d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386960, encodeId=c96b138696010, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著, objectType=article, longId=300955, objectId=f42b30095557, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f42b30095557, replyNumber=0, likeNumber=86, createdTime=2022-03-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f42b30095557, moduleTitle=BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f42b30095557)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386958, encodeId=eb92138695890, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效, objectType=article, longId=300870, objectId=d1753008e0b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1753008e0b3, replyNumber=0, likeNumber=61, createdTime=2022-03-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1753008e0b3, moduleTitle=J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1753008e0b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386959, encodeId=b47e138695984, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=94, createdTime=2022-03-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386956, encodeId=034513869566e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响, objectType=article, longId=300759, objectId=07ff300e59d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ff300e59d0, replyNumber=0, likeNumber=69, createdTime=2022-03-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ff300e59d0, moduleTitle=Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ff300e59d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386957, encodeId=a5ee138695ed9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, objectType=article, longId=300740, objectId=1daa300e408c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa300e408c, replyNumber=0, likeNumber=100, createdTime=2022-03-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa300e408c, moduleTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa300e408c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386955, encodeId=bf23138695555, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=85, createdTime=2022-03-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估

2022-04-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性

2022-04-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Cancer：韩国多中心真实世界研究评估晚期或转移性非小细胞肺癌（NSCLC）免疫治疗的长期临床预后：KCSG LU20-11

2022-04-07

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Front Oncol：局部晚期或转移性食管鳞状细胞癌患者在化疗基础上联合放疗可改善患者预后

2022-04-07

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌

2022-04-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效

2022-04-05

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌

2022-04-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

2022-03-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：达洛鲁胺对转移性激素敏感性前列腺癌生存率的影响

2022-03-26

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响

2022-03-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效

2022-03-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-03-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关

2022-03-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著

2022-03-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效

2022-03-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-03-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响

2022-03-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌

2022-03-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-03-15

科室
- - 订阅+
  - 更多科室
工具
服务